TNFSF10 and breast carcinoma: Lung adenocarcinoma A549 cells, colorectal cancer HT 29 cells, and breast cancer MCF7 cells were chosen for this experiment, as they had previously proven not to be highly sensitive to LUV-TRAIL treatment alone.